Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $165M | $113M | $15M | $1M | $0M | $1M | $1M | $0M | $0M | $0M | $0M | $0M | $1M | $1M |
| Beneficio bruto | $157M | $113M | $15M | $1M | $0M | $1M | $1M | ($9M) | $3M | $0M | $0M | $0M | $1M | $0M |
| % de margen bruto | 95.2% | 99.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -20858.1% | 6717.0% | 100.0% | 100.0% | 100.0% | 100.0% | 57.8% |
| Ingresos operativos (EBIT) | ($253M) | ($256M) | ($344M) | ($362M) | ($351M) | ($330M) | ($221M) | ($67M) | ($98M) | ($99M) | ($124M) | ($239M) | ($6M) | ($2M) |
| % de margen operativo | -153.3% | -226.0% | -2334.2% | -58239.5% | -146374.2% | -35361.9% | -36509.1% | -155597.7% | -209338.3% | -220266.7% | -282954.6% | -101218.6% | -969.1% | -378.2% |
| Ingresos netos | ($992M) | ($351M) | ($414M) | ($583M) | ($417M) | ($347M) | ($222M) | ($66M) | ($96M) | ($96M) | ($121M) | ($237M) | ($6M) | ($2M) |
| % de margen neto | -601.2% | -310.2% | -2804.8% | -93761.4% | -173569.6% | -37129.6% | -36669.6% | -152997.7% | -204736.2% | -214273.3% | -274565.9% | -100371.2% | -969.3% | -341.2% |
| EBITDA | ($889M) | ($224M) | ($264M) | ($479M) | ($352M) | ($321M) | ($204M) | ($57M) | ($87M) | ($91M) | ($118M) | ($236M) | ($6M) | ($2M) |
| Beneficio por acción (EPS) | $-0.97 | $-0.38 | $-0.59 | $-1.15 | $-1.04 | $-0.89 | $-0.58 | $-0.17 | $-0.30 | $-0.30 | $-0.37 | $-0.83 | $-0.02 | $-0.01 |
| Acciones en circulación (M) | 1,050M | 920M | 700M | 509M | 400M | 389M | 383M | 383M | 325M | 322M | 328M | 286M | 316M | 316M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de IBRX. /companies/us/IBRX
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms